People · Operator

Keith M. Nolop

Named in public records as an officer, director or promoter · active 2014–2014 · Biotechnology

1
Companies
1
Filings
$79.1M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Kite Pharma, Inc.BiotechnologySeries C$79.1M$2.0B2014
Operator network

Keith M. Nolop at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Joshua A. Kazam · 10 companies · 1 sharedJoshua A. KazamArie S. Belldegrun · 5 companies · 1 sharedArie S. BelldegrunJonathan M Peacock · 4 companies · 1 sharedJonathan M PeacockAya Jakobovits · 2 companies · 1 sharedAya JakobovitsSteven B. Ruchefsky · 2 companies · 1 sharedSteven B. Ruchefs…Cynthia M. Butitta · 1 companies · 1 sharedCynthia M. ButittaDavid A. Bonderman · 1 companies · 1 sharedDavid A. BondermanFarah B. Champsi · 1 companies · 1 sharedFarah B. ChampsiGloria S. Lee · 1 companies · 1 sharedGloria S. LeeMarc R. Better · 1 companies · 1 sharedMarc R. BetterMargo R. Roberts · 1 companies · 1 sharedMargo R. RobertsRan B. Nussbaum · 1 companies · 1 sharedRan B. NussbaumRizwana R. Sproule · 1 companies · 1 sharedRizwana R. SprouleRoy B. Doumani · 1 companies · 1 sharedRoy B. DoumaniKite Pharma, Inc. · $79.1M raisedKite Pharma, Inc.Keith M. NolopKN
Keith M. Nolop Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Keith M. Nolop on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Joshua A. Kazam110
Arie S. Belldegrun15
Jonathan M Peacock14
Steven B. Ruchefsky12
Aya Jakobovits12
Marc R. Better11
Farah B. Champsi11
Ran B. Nussbaum11
Roy B. Doumani11
Rizwana R. Sproule11
David A. Bonderman11
Gloria S. Lee11
Margo R. Roberts11
Cynthia M. Butitta11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.